Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis
Objective: This exploratory post-hoc analysis evaluated the efficacy and safety of opicapone (OPC) as first-line adjunctive therapy in levodopa/DOPA decarboxylase inhibitors-treated Parkinson’s disease (PD) patients…Effects of onabotulinum toxin A on balance and gait in Parkinson’s disease with foot dystonia: A case series study
Objective: To investigate the effectiveness of botulinum toxin (BoNT) in reducing the severity of dystonia and improving gait and balance in Parkinson’s disease (PD) patients…Beta-adrenoreceptor medications and risk of Parkinson’s disease
Objective: To review and analyze the associations between β-adrenoreceptor medications and risk of Parkinson's disease. Background: Distinctive Lewy body mainly composed of α-synuclein is an…Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Objective: This real-world study evaluated opicapone (OPC) 50-mg in a heterogeneous population of Parkinson’s disease (PD) patients treated in clinical practice. Background: OPC proved effective…Efficacy and safety of levodopa-carbidopa intestinal gel (LCIG) for advanced Parkinson’s disease: a Turkish single-centre experience
Objective: This study is aimed to investigate the efficacy and adverse effect profile of LCIG among advanced PD patients from a Turkish movement disorder center.…Laryngeal movement disorders as a potential clinical biomarker in multiple system atrophy: Results from the LaPD study
Objective: To systematically assess frequency and nature of laryngeal dysfunction in multiples system atrophy (MSA) compared to Parkinson’s disease (PD) and to identify a potential…GCI-induced neurodegeneration and synucleinopathy in non-human primates
Objective: This study aimed at determining the potential to induce MSA pathology in non-human primates. Background: Aggregation of alpha-synuclein has been implicated in several neurodegenerative…Can we stage tau pathology in PSP?
Objective: To evaluate distribution pattern of tau pathology in different PSP clinical subtypes and develop a staging system. Background: Progressive supranuclear palsy (PSP) is a…The effect of comorbid NPH on the clinical feature and progression of Parkinson’s disease
Objective: To analyze the effect of co-existing normal pressure hydrocephalus (NPH) on the clinical course of Parkinson's disease (PD), we examined the disease progression and…Serum neurofilament light chain differentiates early Parkinson’s disease from progressive supranuclear palsy-parkinsonism
Objective: To assess the value of serum neurofilament light chain (NFL) levels in differentiating parkinsonian syndromes. Background: The diagnosis of Parkinson’s disease (PD) mostly relies…
- « Previous Page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- …
- 149
- Next Page »